Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
Portfolio Pulse from
Theralase Technologies Inc. announced that its product, Rutherrin, has shown efficacy in destroying Non-Hodgkin's Lymphoma in animal models when combined with Metformin and radiation.
February 25, 2025 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theralase Technologies Inc. reported that its product, Rutherrin, effectively destroyed Non-Hodgkin's Lymphoma in animal models when used with Metformin and radiation.
The news highlights a significant development for Theralase's product, Rutherrin, which could lead to further research and potential human trials. This positive development may boost investor confidence and interest in TLTFF.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100